Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Source: SeekingAlpha
2026-03-26 07:30:42 ET
Overview
Liquidia's stock ( LQDA ) is up a solid 16% since my " Sell " rating to begin the year. Its commercialization of Yutrepia (treprostinil powder) has gone quite well....
Read the full article on Seeking Alpha
For further details see:
Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Insmed Incorporated
NASDAQ: INSM
INSM Trading
1.67% G/L:
$164.94 Last:
1,114,741 Volume:
$164.49 Open:
INSM Latest News
March 23, 2026 07:00:00 am
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
February 19, 2026 07:00:00 am
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
INSM Stock Data
$31,647,650,065
206,875,265
0.18%
273
N/A
Biotechnology & Life Sciences
Healthcare
US
Bridgewater
